AKBA News - Candlesense

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:AKBA) CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted b...

Governance

9 days ago

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impac...

Are there any supply chain, pricing, or reimbursement risks associated with scaling Vafseo® across all IRC clinics that could influence the stock's volatility? What is the expected market share gain for Vafseo® versus existing anemia treatments in the dialysis space, and how might that impact competitor valuations? How will the nationwide launch of Vafseo® affect Akebia Therapeutics' revenue forecasts and earnings guidance?

Product launch

21 days ago